MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that clinical data from three clinical trials of its anti-cancer drug nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, were presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 30 to June 3, 2008.
"The breadth of data presented at ASCO highlights the promise nimotuzumab holds for a diverse group of oncology patients," said David Allan, Chairman and CEO of YM BioSciences. "In each of these trials, results further demonstrated the unique potential for nimotuzumab to be an effective EGFR-targeting antibody without deleterious side-effects observed with the other drugs in its class."
"Phase III trial of nimotuzumab for the treatment of newly diagnosed
diffuse intrinsic pontine gliomas in children and adolescents" (Abstract
This poster reported data from a multi-centre Phase III study evaluating the feasibility and efficacy of nimotuzumab as the primary treatment for these patients. Between March 2006 and August 2007, 42 patients aged 3 to 16 years (median 7 years) were enrolled in this study, with 41 patients evaluable for response. The primary endpoint for the trial is median progression free survival at six months after diagnosis. Secondary endpoints include overall survival, response rate, toxicity and quality of life.
The poster presentation described preliminary results including that
the median progression free survival was 5.9 months, that the median
|SOURCE YM BioSciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved